Cancer neoantigen: Boosting immunotherapy

被引：42
|
作者：
Xu, Peijia [1 ,2 ,3 ]
Luo, Haiqing [4 ]
Kong, Ying [5 ]
Lai, Wing-Fu [6 ,7 ]
Cui, Liao [1 ,2 ]
Zhu, Xiao [1 ,2 ,3 ,8 ]
机构：
[1] Guangdong Med Univ, Marine Biomed Res Inst, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang 524023, Peoples R China
[2] Marine Biomed Res Inst Guangdong Zhanjiang, Zhanjiang 524023, Peoples R China
[3] Guangdong Med Univ, Key Lab Zhanjiang R&D Marine Microbial Resources, Zhanjiang 524023, Peoples R China
[4] Guangdong Med Univ, Affiliated Hosp, Canc Ctr, Zhanjiang 524023, Peoples R China
[5] Jianghan Univ, Peoples Hosp 3, Dept Clin Lab, Wuhan 430033, Peoples R China
[6] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Peoples R China
[7] Chinese Univ Hong Kong Shenzhen, Sch Life & Hlth Sci, Shenzhen, Peoples R China
[8] Southern Marine Sci & Engn Guangdong Lab Zhanjian, Zhanjiang 524023, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2020年 / 131卷
基金：
中国国家自然科学基金;
关键词：
Neoantigen; Personalized vaccine; Tumor mutational burden; Melanoma; Immunotherapy; CLASS-II; TUMOR; SURVIVAL; ANTIBODY; IMMUNITY; MELANOMA; PD-1;
D O I：
10.1016/j.biopha.2020.110640
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Tumor neoantigen has a high degree of immunogenicity. As one of the emerging methods of tumor immunotherapy, the vaccine developed against it has served to clinical trials of various solid tumors, especially in the treatment of melanoma. Currently, a variety of immunotherapy methods have been applied to the treatment of the tumor. However, other therapeutic methods have the disadvantages of low specificity and prominent side effects. Treatments require tumor antigen with higher immunogenicity as the target of immune attack. This review will recommend the identification of neoantigen, the influencing factors of neoantigen, and the application of personalized vaccines for neoantigen in metastatic tumors such as malignant melanoma.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Microbial neoantigen vectors for cancer immunotherapy
    Redenti, Andrew A.
    Danino, Tal
    Arpaia, Nicholas
    [J]. CANCER RESEARCH, 2023, 83 (07)
  • [2] Neoantigen-based cancer immunotherapy
    Bobisse, Sara
    Foukas, Periklis G.
    Coukos, George
    Harari, Alexandre
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (14)
  • [3] The Value of Microbes in Cancer Neoantigen Immunotherapy
    Tian, Junrui
    Ma, Jian
    [J]. PHARMACEUTICS, 2023, 15 (08)
  • [4] Boosting cancer immunotherapy
    Ioana Visan
    [J]. Nature Immunology, 2013, 14 (8) : 776 - 776
  • [5] Neoantigen: A Long March toward Cancer Immunotherapy
    Liu, Yang
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2602 - 2604
  • [6] Neoantigen cancer immunotherapy enters clinical trials
    不详
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (05) : 968 - 968
  • [7] Neoantigen nanovaccine improves personalized cancer immunotherapy
    Mi, Yu
    Smith, Christof C.
    Serody, Jonathan S.
    Vincent, Benjamin G.
    Wang, Andrew Z.
    Hyun, Hyesun
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [8] Advances in personalized neoantigen vaccines for cancer immunotherapy
    Sun, Changbo
    Xu, Shun
    [J]. BIOSCIENCE TRENDS, 2020, 14 (05) : 349 - 353
  • [9] Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer
    Zheng, Yue
    Fu, Yang
    Wang, Pei-Pei
    Ding, Zhen-Yu
    [J]. DISEASE MARKERS, 2022, 2022
  • [10] Engineering neoantigen vaccines to improve cancer personalized immunotherapy
    Liu, Zaoqu
    Lv, Jinxiang
    Dang, Qin
    Liu, Long
    Weng, Siyuan
    Wang, Libo
    Zhou, Zhaokai
    Kong, Ying
    Li, Huanyun
    Han, Yilin
    Han, Xinwei
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (15): : 5607 - 5623
12345